Pharmacokinetics and biodistribution of genetically engineered antibodies.
The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.
Batra
Surinder K
SK
Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA. sbatra@unmc.edu
Jain
Maneesh
M
Wittel
Uwe A
UA
Chauhan
Subhash C
SC
Colcher
David
D
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000493:pharmacokinetics*; D003001:Cloning, Molecular / Q000379:methods; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D051379:Mice; D009369:Neoplasms / Q000378:metabolism*; D015202:Protein Engineering / Q000379:methods*; D014018:Tissue Distribution
D000906:Antibodies; D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments